semaglutide and retinal detachment Association between various dosage forms of ocular adverse events in a real-world setting Semaglutide linked to increased risk

Semaglutide Kidney Study Ends Early for Early Efficacy On October 10, 2023, Novo Nordisk announced the early termination of a Phase 3 clinical trial of semaglutide for the treatment of patients with kidney injury and chronic kidney disease who have type 2 diabetes

In younger patients, this is manageable with adequate protein intake and resistance exercise

Motor symptoms remained relatively stable in the treatment group, while the placebo group experienced progressive decline

The medication biologically suppresses patients desire to eat, but that doesnt mean it suppresses their need to eat. And although protein, the macronutrient de jour, is a critical element for people taking GLP-1s, its not the be-all end-all

For patients interested in personalized genetic insights, the PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes how your genetic variantsincluding GLP1R rs6923761 and GIPR rs1800437affect your response to GLP-1 therapy

Protective role of serpina3c as a novel thrombin inhibitor against atherosclerosis in mice